Tuesday, June 13, 2023 7:52:33 AM
June 12 2023 - 06:23PM
GlobeNewswire Inc.
Alert
Share On Facebook
Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that three posters will be presented at ASM Microbe 2023 conference.
The hybrid conference will be held from June 15-19 at the George R. Brown Convention Center in Houston, TX.
Data to be presented include:
Presentation title: ß-Lactamase Characterization of Baseline Enterobacterales Pathogens from a Phase 3 Trial of Sulopenem for the Treatment of Uncomplicated Urinary Tract Infection
Presentation type/category: P002-AAR01 Surveillance of antimicrobial resistance in clinical isolates; ß-lactamases (AAR-Friday-410)
Presenter: Steven I. Aronin, MD
Time/location: June 16, 2023, 10:00 a.m. – 5:00 p.m. CDT; Exhibit and Poster Hall B, C, D
Presentation title: ß-Lactamase Characterization of Baseline Enterobacterales Pathogens from a Phase 3 Trial of Sulopenem for the Treatment of Complicated Urinary Tract Infection
Presentation type/category: P002-AAR01 Surveillance of antimicrobial resistance in clinical isolates; ß-lactamases (AAR-Friday-417)
Presenter: Sailaja Puttagunta, MD
Time/location: June 16, 2023, 10:00 a.m. – 5:00 p.m. CDT; Exhibit and Poster Hall B, C, D
Presentation title: ß-Lactamase Characterization of Baseline Enterobacterales Pathogens from a Phase 3 Trial of Sulopenem for the Treatment of Complicated Intraabdominal Infection
Presentation type/category: P002-AAR01 Surveillance of antimicrobial resistance in clinical isolates; ß-lactamases (AAR-Friday-401)
Presenter: Sailaja Puttagunta, MD
Time/location: June 16, 2023, 10:00 a.m. – 5:00 p.m. CDT; Exhibit and Poster Hall B, C, D
These Posters will be made available on the Company’s website on the “Publications: Posters & Presentations” page under the “Our Science” tab once the conference ends.
About Iterum Therapeutics plc
Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum Therapeutics is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum Therapeutics has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications.
Investor Contact:
Judy Matthews
Chief Financial Officer
312-778-6073
IR@iterumtx.com
Recent ITRM News
- Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem • GlobeNewswire Inc. • 04/29/2024 12:00:00 PM
- US Stock Futures Stable in Pre-Market On Path for Consecutive Quarterly Gains, Oil Prices Rise • IH Market News • 03/28/2024 11:42:00 AM
- Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/28/2024 11:00:00 AM
- Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024 • GlobeNewswire Inc. • 03/21/2024 08:30:00 PM
- Iterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside Chat • GlobeNewswire Inc. • 03/15/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 01:16:14 PM
- Iterum Therapeutics Provides Business Update • GlobeNewswire Inc. • 03/06/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 10:00:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 12:15:32 PM
- Iterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections • PR Newswire (US) • 01/30/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/29/2023 09:30:15 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 12/14/2023 12:45:02 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/14/2023 12:30:02 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 12/04/2023 10:15:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/04/2023 10:00:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/04/2023 01:30:09 PM
- Iterum Therapeutics Regains Compliance with Nasdaq Bid Price Rule • GlobeNewswire Inc. • 12/04/2023 01:00:00 PM
- Iterum Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on November 14, 2023 • GlobeNewswire Inc. • 11/07/2023 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2023 01:00:11 PM
- Iterum Therapeutics Announces Completion of Enrollment in its REASSURE Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections • GlobeNewswire Inc. • 10/24/2023 12:00:00 PM
- Iterum Therapeutics to Present Data at IDWeek 2023 • GlobeNewswire Inc. • 10/12/2023 01:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/11/2023 11:15:58 AM
- Iterum Therapeutics Reports Second Quarter 2023 Financial Results • GlobeNewswire Inc. • 08/11/2023 11:00:00 AM
- Iterum Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 11, 2023 • GlobeNewswire Inc. • 08/04/2023 09:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2023 08:16:04 PM
FEATURED Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
Avant Technologies to Implement AI-Empowered, Zero Trust Architecture in Its Data Centers • AVAI • Apr 29, 2024 8:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM